OCU400 is Ocugen’s novel modifier gene therapy for retinitis pigmentosa (RP). The OCU400 (AAV5-h NR2E3) gene therapy platform ...

Kiora Pharmaceuticals has granted Senju Pharmaceutical an exclusive option to exercise rights to an exclusive development and ...

VG801 is a dual AAV gene therapy that leverages mRNA trans-splicing via the vgRNA REVeRT and vgAAV platforms to deliver the ...

Boyer discusses a potential treatment for diabetic retinopathy and macular degeneration using suprachoroidal injections, ...

IVMED-85 is a preservative-free, non-atropine daily drop that slows myopia progression by strengthening scleral and corneal ...

Ophthalmology Times connects eye care professionals with surgery, imaging, gene therapy, & diagnostic advances to enhance ...

Weighing the benefits and trade-offs of preserved versus preservative-free glaucoma treatments is key to optimizing long-term ...

Retinal vascular change or degeneration already has been associated with Alzheimer and Parkinson disease, and the findings ...

SpyGlass Pharma secures $75 million in Series D funding to enhance its innovative drug delivery platform for long-term ...

Prevent Blindness offers resources for Cataract Month, empowering patients and caregivers with knowledge on cataracts and ...

A recent US Court of International Trade decision was made on May 28 to permanently prohibit all tariffs imposed by President ...

The phase 3 trial observed the treatment of chronic night driving impairment in keratorefractive patients with reduced ...